FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906202227> ?p ?o ?g. }

• W2906202227 abstract "Objective: To report the baseline characteristics of patients with relapsing-remitting multiple sclerosis (RRMS) who enrolled in the prospective, multicenter, open-label, Phase IIIB CHORDS study (NCT02637856) evaluating the effectiveness and safety of ocrelizumab in patients who had a suboptimal response to an adequate course of a disease-modifying therapy (DMT). Background: Patients with RRMS often experience disease activity despite receiving a DMT. Ocrelizumab demonstrated superior efficacy compared with interferon beta-1a in two Phase III trials (OPERA I; OPERA II) in patients with relapsing MS. Design/Methods: Key eligibility criteria included disease duration ≤12 years, prior treatment of ≥6 months with ≥1 DMT, with exposure to ≤3 DMTs, and the discontinuation of the most recent DMT due to suboptimal disease control, defined as ≥1 clinically reported relapse, ≥1 T1 gadolinium-enhancing lesions or ≥2 new/enlarging T2 lesions. Ocrelizumab is being administered as a 600-mg intravenous infusion every 24 weeks, up to ≥96 weeks, for 4 doses, with the initial dose given as two 300-mg infusions, 14 days apart. Results: In the CHORDS study, 608 patients (72% female) were enrolled and treated, with a mean (SD) age of 37.2 (8.6) years at baseline. The mean (SD) baseline EDSS score was 2.5 (1.3); mean (SD) duration since first MS symptom onset was 5.4 (3.2) years. Most patients had received one (56%) or two (36%) DMTs prior to enrollment. The most commonly used DMT immediately before enrollment was glatiramer acetate (49%). The most frequent qualifying event for study inclusion was a clinical relapse; 44% of patients had ≥1 relapse, without evidence of MRI activity, at enrollment. Conclusions: The CHORDS study, conducted in the USA and Canada, will describe the effectiveness and safety of ocrelizumab treatment in patients who are early in their disease course and had ongoing disease activity while receiving another DMT. Study Supported by: Sponsored by Genentech, Inc. Disclosure: Dr. Reder has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Bayer, Genzyme, Genentech. Dr. Reder has received personal compensation in an editorial capacity for Medlink. Dr. Reder has received research support from Biogen, Novartis, Bayer, Malinkrodt, Serono, Genentech. Dr. Bermel has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Genzyme, Genentech, Novartis. Dr. Weinstock-Guttman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bianca Weinstock- Guttman received honoraria as a speaker and as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, GenzymeS Novartis, Biogen, Chugai, Alkermes, Genentech. Dr. Cutter has nothing to disclose. Dr. Stankiewicz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech, Genzyme, Teva neuroscience, Bayer, Novartis, Biogen Idec. Dr. Zheng has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Compensation from Genentech and stock in F. Hoffmann-La Roche Ltd as Genentech employee. Dr. Musch has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech. Dr. Csoboth has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Compensation from Genentech and stock in F. Hoffmann-La Roche Ltd as Genentech employee. Dr. Wolinsky has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with has served on advisory boards and data monitoring or steering committees, has held consulting agreements or has received speaker honoraria from AbbVie, Alkermes, Biogen, Bionest, Clene Nanomedicine, EMD Serono, Forward Pharma, MedDay, Pharmaceuticals, Nov. Dr. Wolinsky has received royalty, license fees, or contractual rights payments from royalties for monoclonal antibodies out-licensed to Chemicon International through UTHealth." @default.
• W2906202227 created "2019-01-01" @default.
• W2906202227 creator A5002621424 @default.
• W2906202227 creator A5002866949 @default.
• W2906202227 creator A5023547051 @default.
• W2906202227 creator A5041165817 @default.
• W2906202227 creator A5057717799 @default.
• W2906202227 creator A5075596287 @default.
• W2906202227 creator A5076338840 @default.
• W2906202227 creator A5076423610 @default.
• W2906202227 creator A5079294050 @default.
• W2906202227 creator A5087151734 @default.
• W2906202227 creator A5090919263 @default.
• W2906202227 date "2018-04-10" @default.
• W2906202227 modified "2023-10-17" @default.
• W2906202227 title "Baseline Characteristics of the CHORDS Study Population: A Phase III Trial to Evaluate the Effectiveness and Safety of Ocrelizumab in Patients With RRMS Who Had Disease Activity With Prior Disease-Modifying Therapies (P6.370)" @default.
• W2906202227 hasPublicationYear "2018" @default.
• W2906202227 type Work @default.
• W2906202227 sameAs 2906202227 @default.
• W2906202227 citedByCount "0" @default.
• W2906202227 crossrefType "journal-article" @default.
• W2906202227 hasAuthorship W2906202227A5002621424 @default.
• W2906202227 hasAuthorship W2906202227A5002866949 @default.
• W2906202227 hasAuthorship W2906202227A5023547051 @default.
• W2906202227 hasAuthorship W2906202227A5041165817 @default.
• W2906202227 hasAuthorship W2906202227A5057717799 @default.
• W2906202227 hasAuthorship W2906202227A5075596287 @default.
• W2906202227 hasAuthorship W2906202227A5076338840 @default.
• W2906202227 hasAuthorship W2906202227A5076423610 @default.
• W2906202227 hasAuthorship W2906202227A5079294050 @default.
• W2906202227 hasAuthorship W2906202227A5087151734 @default.
• W2906202227 hasAuthorship W2906202227A5090919263 @default.
• W2906202227 hasConcept C126322002 @default.
• W2906202227 hasConcept C203014093 @default.
• W2906202227 hasConcept C2778577042 @default.
• W2906202227 hasConcept C2778715236 @default.
• W2906202227 hasConcept C2778843634 @default.
• W2906202227 hasConcept C2779134260 @default.
• W2906202227 hasConcept C2779338263 @default.
• W2906202227 hasConcept C2780640218 @default.
• W2906202227 hasConcept C2780653079 @default.
• W2906202227 hasConcept C2908647359 @default.
• W2906202227 hasConcept C71924100 @default.
• W2906202227 hasConcept C99454951 @default.
• W2906202227 hasConceptScore W2906202227C126322002 @default.
• W2906202227 hasConceptScore W2906202227C203014093 @default.
• W2906202227 hasConceptScore W2906202227C2778577042 @default.
• W2906202227 hasConceptScore W2906202227C2778715236 @default.
• W2906202227 hasConceptScore W2906202227C2778843634 @default.
• W2906202227 hasConceptScore W2906202227C2779134260 @default.
• W2906202227 hasConceptScore W2906202227C2779338263 @default.
• W2906202227 hasConceptScore W2906202227C2780640218 @default.
• W2906202227 hasConceptScore W2906202227C2780653079 @default.
• W2906202227 hasConceptScore W2906202227C2908647359 @default.
• W2906202227 hasConceptScore W2906202227C71924100 @default.
• W2906202227 hasConceptScore W2906202227C99454951 @default.
• W2906202227 hasOpenAccess W2906202227 @default.
• W2906202227 hasRelatedWork W2779339208 @default.
• W2906202227 hasRelatedWork W2791646516 @default.
• W2906202227 hasRelatedWork W2802044471 @default.
• W2906202227 hasRelatedWork W2802779394 @default.
• W2906202227 hasRelatedWork W2805787161 @default.
• W2906202227 hasRelatedWork W2808793551 @default.
• W2906202227 hasRelatedWork W2810214780 @default.
• W2906202227 hasRelatedWork W2823358944 @default.
• W2906202227 hasRelatedWork W2883731232 @default.
• W2906202227 hasRelatedWork W2883823502 @default.
• W2906202227 hasRelatedWork W2887168480 @default.
• W2906202227 hasRelatedWork W2893104962 @default.
• W2906202227 hasRelatedWork W2894648148 @default.
• W2906202227 hasRelatedWork W2952144592 @default.
• W2906202227 hasRelatedWork W2965032871 @default.
• W2906202227 hasRelatedWork W3111961654 @default.
• W2906202227 hasRelatedWork W3126794321 @default.
• W2906202227 hasRelatedWork W3174653963 @default.
• W2906202227 hasRelatedWork W3194937453 @default.
• W2906202227 hasRelatedWork W3202775233 @default.
• W2906202227 hasVolume "90" @default.
• W2906202227 isParatext "false" @default.
• W2906202227 isRetracted "false" @default.
• W2906202227 magId "2906202227" @default.
• W2906202227 workType "article" @default.